A four-month build.
A live system.
Yours.

Subject: AbVision's cell therapy pipeline and manufacturing readiness Hi Gloria, AbVision's approach to harnessing antibody discoveries for immune-based cancer therapeutics is compelling, especially as you advance toward clinical development. The transition from preclinical to Phase I often reveals manufacturing bottlenecks that weren't apparent at smaller scales. Many cell therapy developers we work with face viability loss during scale-up, particularly when transitioning from research-grade to clinical manufacturing processes. At Carr, our tubular bowl centrifugation platform consistently delivers >95% cell viability across CAR-T and other immune cell types, maintaining the critical quality attributes that determine therapeutic efficacy. Our applications team has supported several Bay Area biotechs through this exact transition, helping establish scalable processes early to avoid costly tech transfer delays later in development. Would you have 15-20 minutes next week to discuss how manufacturing strategy might impact your clinical timeline? Best regards, Bethanne Deuel CARR Biosystems

Subject: Avobis Bio's MSC programs and processing considerations Hi Betty, Avobis Bio's approach to combining mesenchymal stem cells with bioabsorbable scaffolds represents a compelling strategy for regenerative healing. As your programs advance through clinical development, maintaining consistent MSC quality becomes increasingly critical under regulatory scrutiny. Many teams we work with face challenges preserving MSC viability during harvest and concentration steps, especially when scaling protocols for higher clinical volumes. At Carr, our tubular bowl centrifugation technology consistently delivers >95% cell viability while minimizing the shear stress that can compromise MSC therapeutic properties. Our applications team has supported several MSC-focused companies through similar scale-up transitions, helping them establish robust processing workflows that maintain cell quality attributes from development through commercial manufacturing. Would you have 15-20 minutes next week to discuss how other teams have addressed MSC processing challenges during clinical advancement? Best regards, Bethanne Deuel CARR Biosystems

Subject: Scaling CAR-NK manufacturing at Coeptis Hi Dan, Coeptis's CAR-NK platform represents a compelling approach to solid tumor targeting, especially as you advance through clinical development. The challenge many teams face at your stage is ensuring the manufacturing processes that worked in early development can scale seamlessly to support later-phase trials without compromising cell quality. At Carr, our applications team regularly works with CAR-NK developers who need to maintain >95% viability while scaling from bench to GMP volumes. Our closed-system platform consolidates harvest, wash, and concentration steps that traditionally require multiple pieces of equipment and extensive manual intervention. We've seen similar clinical-stage companies reduce their tech transfer timelines significantly by implementing scalable bioprocessing early, before GMP requirements lock in suboptimal workflows. Would you have 15-20 minutes next week to discuss how other CAR-NK teams have approached scalable cell processing? Best regards, Nico Summaria CARR Biosystems

Subject: NG01 manufacturing considerations for pivotal trials Hi Dorit, NeuroGenesis's NG01 platform for transforming marrow-derived cells into neuroprotective bio-factories represents a compelling approach to progressive MS and ALS. As you advance through clinical development, maintaining patient-specific batch integrity becomes increasingly critical under regulatory scrutiny. Autologous manufacturing introduces unique challenges around cross-contamination prevention and per-patient traceability that traditional processing equipment wasn't designed to handle. At Carr, our single-use tubular bowl centrifugation maintains >95% viability while providing complete lot documentation and gamma-irradiation records for each patient batch. Our applications team has worked extensively with clinical-stage cell therapy companies navigating similar autologous manufacturing requirements, particularly around 21 CFR Part 11 compliant data logging and batch-to-batch consistency. Would you have 15-20 minutes next week to discuss how automated, closed-system processing could support NG01's path through pivotal trials? Best regards, Nico Summaria CARR Biosystems

Subject: BioStem's BioRetain processing and scaling considerations Hi Andrew, BioStem's focus on preserving tissue structure and growth factors through the BioRetain method represents a thoughtful approach to perinatal tissue processing. As you scale manufacturing operations for your regenerative therapy portfolio, maintaining those critical quality attributes becomes even more challenging. Many tissue banking operations we work with face viability losses during scale-up when moving from manual processing to larger volumes. At Carr, our closed-system centrifugation platform has helped similar companies maintain >95% cell viability while scaling from 500 mL development runs to 2,000 L commercial batches without technology changes. Our applications team has worked extensively with regenerative medicine companies navigating the transition from research-grade processing to GMP manufacturing, particularly around maintaining consistent concentration factors and cell quality across scales. Would you have 15-20 minutes next week to discuss how other tissue banking operations have addressed scaling challenges while preserving their proprietary processing advantages? Best regards, Jeff Plambeck CARR Biosystems

Subject: MightyTIL scale-up considerations Hi Lyndsey, TrAMPoline's engineered TIL approach with enhanced anti-tumor activity sounds promising, especially with the preclinical data you're generating. As you move toward IND-enabling studies, the transition from discovery-scale TIL expansion to GMP-ready processes often creates unexpected bottlenecks. Many teams we work with hit viability drops during scale-up when switching separation technologies between development and manufacturing. At Carr, our tubular bowl centrifugation maintains >95% TIL viability while providing the throughput needed for patient doses, using the same low-shear technology from lab through commercial scale. Our applications team has been working with several TIL developers on process design early in development to avoid costly tech transfer issues later. We've seen this approach save months in IND timelines. Would you have 20 minutes next week to discuss how other TIL companies have approached scalable bioprocessing workflows? Best regards, Jeff Plambeck CARR Biosystems